- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01874197
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic (B-TEVAR)
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic Aneurysms: An Investigator-Initiated Study
An investigator-initiated, prospective, consecutively enrolling, non-randomized single institution clinical evaluation of the safety and effectiveness of branched and fenestrated-branched endovascular stent grafts to preserve branch vessels when used in the treatment of patients with thoraco-abdominal aortic aneurysms. The study evaluates non-FDA-approved off the shelf and custom made branched and fenestrated-branched stent grafts manufactured by Cook Medical.
The primary objectives of this study are to determine whether fenestrated-branched and branched endovascular grafts are a safe and effective method of treating patients with thoraco-abdominal aortic aneurysms.
Study Overview
Status
Intervention / Treatment
Detailed Description
A branched thoracic endograft is a commercially manufactured endograft that has reinforced fenestrations or branches in the graft through which covered stent grafts can be deployed to preserve blood flow into visceral branch vessels.
The branched stent graft is deployed to reline the peri-visceral abdominal aorta. Proximal and distal fixation and seal can be achieved using the branched device, additional Cook Alpha Thoracic devices and/or the Cook Zenith® Flex® device depending on the aortic anatomy.
Once the aortic stent grafts are deployed, the branches are then created. Wires and catheters are used to cross through the reinforced fenestrations into the target visceral arteries. Covered stents are then deployed to extend from the modified aortic graft to the target vessel. The branch stents must create a hemostatic seal with the main endograft as these branches will be constructed within the aneurysm sac. Single or multiple stents may be required for any given branch.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Margo Godersky, MPH
- Phone Number: 2065988487
- Email: BTEVAR@uw.edu
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- University of Washington/Harborview Medical Center
-
Contact:
- Matthew Sweet, MD
-
Contact:
- Email: BTEVAR@uw.edu
-
Principal Investigator:
- Matthew P Sweet, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:
- Patient is > 18 years of age
- Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
- Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form
- Patient is considered by the treating physician to be at high risk of open surgical repair due to one or more major medical co-morbidities (i.e. CAD, CHF, COPD, CRI, advanced age, generalized deconditioning, or other.) with ASA of 3 or more.
- The patient has a life expectancy of greater than 1 year.
- The patient has a thoraco-abdominal aortic aneurysm where necessary visceral branch vessels (i.e. the celiac, superior mesenteric, inferior mesenteric, renal and/or dominant spinal arteries) arise from the aneurysm or seal zones necessary for on-label thoracic endovascular repair
Patient has a thoraco-abdominal aortic aneurysm that meets at least one of the following:
- aneurysm > 5.5 cm in diameter
- aneurysm has increased in size by 0.5 cm in last 6 months
- aneurysm is believed to be causing symptoms
- Patient has sufficient arterial access (femoral and/or iliac) that will allow delivery of the endovascular device with or without the use of a surgical conduit.
- Patient has suitable proximal (aorta) and distal (aorta or iliac) arteries to allow for adequate fixation and seal:
A. Non-aneurysmal proximal aortic seal zone:
- with a length of 25 mm of proximal seal in non-aneurysmal aorta, with or without coverage of the left subclavian artery,
with an outer wall diameter of no less than 20 mm and no greater 38mm, and
B. Non-aneurysmal distal aortic or iliac landing zone:
- With a length of at least 15 mm,
- Aortic seal zone no less than 15 mm and no greater than 38 mm or Iliac seal zone with an outer wall diameter of no less than 8 mm and no greater than 23 mm.
10. The patient has no more than 5 necessary visceral arteries that require flow preservation.
11. All target visceral artery seal zones are > 4 mm in diameter. 12. Patient must be willing to comply with all required follow-up exams.
Exclusion Criteria:
Patients that meet ANY of the following are not eligible for enrollment into the study:
- Patient has an active systemic infection
- Patient has a mycotic aneurysm.
- Patient has a known hypersensitivity to contrast media that is not amenable to pre-treatment.
- Patient has an absolute contra-indication to anticoagulation
- Patient has a known allergy or intolerance to stainless steel, nickel, or gold
- Patient has a body habitus that would inhibit adequate X-ray visualization of the aorta
- Patient has a dominant artery to the spinal cord arising from an area of stent graft coverage that is not amenable to preservation using an endovascular branch
- Patient is currently participating in another investigational device or drug clinical trial
- Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
- Patient has a freely ruptured TAAA with hemodynamic instability
- Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
- Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned within 30 days of the TAAA repair. Adjunctive procedures for treatment of the TAAA (i.e. carotid-subclavian bypass or iliac conduit) are acceptable.
- Patient has a history of connective tissue disease (e.g. Marfan or Ehlers Danlos syndromes)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: B -TEVAR
Implantation of the B-TEVAR device
|
Creation and implantation of the Branched Thorcoabdominal aortic anerysm device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The effectiveness of multi-branched endovascular grafts will be determined by evaluating the proportion of patients that achieve Treatment Success
Time Frame: 12 months post-procedure.
|
12 months post-procedure.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality rates
Time Frame: 12 months
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: 12 months
|
Technical Success is defined as successful delivery and deployment of the physician modified graft with preservation of unimpeded flow to those branch vessels intended to be preserved.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matthew P Sweet, MD, University of Washington
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004379
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracoabdominal Aortic Aneurysm, Without Rupture
-
Rede Optimus Hospitalar SAShockwave Medical, Inc.Not yet recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm Without Rupture | Thoracic Aortic Aneurysm Without Rupture
-
Dr. Sabrina OverhagenActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm, Without Mention of RuptureGermany
-
Dr. Sabrina OverhagenBentley InnoMed GmbHActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of RuptureGermany
-
University of BolognaCompletedThoracoabdominal Aortic Aneurysm | Ruptured Thoracic Aneurysm | Ruptured Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm, RupturedItaly
-
The Christ HospitalMedtronicRecruiting
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
University of South FloridaMedtronic; Sanford HealthActive, not recruiting
-
EndologixActive, not recruitingAbdominal Aortic Aneurysm Without RuptureUnited States
-
Imperial College LondonThe British Society of Endovascular Therapy (BSET)CompletedAbdominal Aortic Aneurysm Without RuptureUnited Kingdom
-
Hospital Sao JoaoCompletedAbdominal Aortic Aneurysm Without RupturePortugal
Clinical Trials on B-TEVAR device
-
University of MichiganTerminatedThoracic Aortic AneurysmUnited States
-
Endovascular FoundationW.L.Gore & Associates; Bocconi UniversityRecruitingThoracic Aorta | Thoracic Aorta Aneurysm | Thoracic Aorta AbnormalitySpain, Italy
-
Assiut UniversityNot yet recruitingType B Aortic DissectionEgypt
-
Medtronic CardiovascularCompletedAortic Diseases | Aortic Aneurysm, Thoracic | Penetrating Ulcer | Descending Thoracic Aortic Dissection | Aorta Thoracic; Traumatic RuptureFrance
-
Philips Clinical & Medical Affairs GlobalCompletedCarotid Stenosis | Abdominal Aortic Aneurysm (AAA) | Thoracic Aortic Aneurysm (TAA) | Visceral Artery AneurysmUnited States
-
Ospedale San DonatoUniversity of PaviaUnknownAortic Diseases | Aortic Dissection | Thoracic Aortic AneurysmItaly
-
Oticon MedicalCompletedNervous System Diseases | Neurologic Manifestations | Otorhinolaryngologic Diseases | Ear Diseases | Sensation Disorders | Hearing Loss | Hearing Disorders | Deafness | Hearing Loss, Conductive | Hearing Loss, MixedDenmark
-
Mahidol UniversityRecruitingLung Cancer | Aortic Aneurysm | Aortic Dissection | MoralityThailand
-
Ospedale San DonatoRecruitingAortic Diseases | Aortic Arch | Bovine ArchItaly
-
Cook Group IncorporatedWilliam Cook Europe; MED Institute, Incorporated; William Cook AustraliaCompletedThoracic Aortic AneurysmUnited States, Italy, Canada